Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2003
Business Overview: Gilead is a biopharmaceutical company focused on the discovery, development, and commercialization of antivirals, antibacterials, and antifungals. Key marketed products include Viread and Emtriva (HIV), Hepsera (Hepatitis B), AmBisome (antifungal), DaunoXome, and Vistide. The company also earns royalties from Tamiflu (marketed by Roche).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2003 |
Six Months Ended June 30, 2003 |
Six Months Ended June 30, 2002 |
|---|---|---|---|
| Total Revenues | $238,870 | $403,975 | $187,779 |
| Net Income (Loss) | $100,372 | $(337,682) | $15,861 |
| Net Income (Loss) Per Share (Diluted) | $0.46 | $(1.69) | $0.08 |
| Operating Cash Flow | N/A | $80,384 | $(21,905) |
| Cash and Cash Equivalents | $169,355 | $169,355 | $83,157 |
| Marketable Securities | $512,088 | $512,088 | N/A |
| Total Debt (Convertible) | $595,000 | $595,000 | N/A |
| Product Gross Margin | 86.1% | 86.2% | 81.9% |
Note: Debt consists of $345 million in 2% convertible senior debt and $250 million in 5% convertible subordinated debt.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 118% year-over-year for the quarter and 115% for the six-month period. Product sales surged 146% in the quarter, driven primarily by Viread sales which grew from $44.7 million to $167.0 million.
- Profitability Volatility: While the company reported a net income of $100.4 million for the quarter, the six-month period resulted in a net loss of $337.7 million. This loss is primarily due to a one-time non-cash charge of $488.6 million for in-process research and development (IPR&D) related to the acquisition of Triangle Pharmaceuticals, Inc.
- Expense Increases: R&D expenses increased 26% for the quarter and 24% for the six months, attributed to clinical trials for Emtriva and Triangle assets. SG&A expenses increased 45% for the quarter due to expanded sales forces for Viread and Hepsera.
- Liquidity: Cash and cash equivalents decreased from $616.9 million at year-end 2002 to $169.4 million at June 30, 2003, largely due to the $375.5 million net cash outflow for the Triangle acquisition.
Guidance, Outlook, and Risks
Management Commentary and Guidance
- Viread: Full-year 2003 sales expected to range between $550 million and $600 million. Management noted that Q2 sales were boosted by $25-$30 million in wholesaler stocking ahead of a price increase, which may negatively impact Q3 sales.
- AmBisome: Full-year 2003 sales expected to range between $170 million and $180 million, representing a 5-10% decrease from 2002 due to increased competition in Europe.
- Expenses: Full-year 2003 R&D expenses projected at $165-$180 million; SG&A expenses projected at $240-$260 million.
Risks and Contingencies
- Regulatory Actions: On August 7, 2003, the FDA issued a written warning regarding promotional practices for Viread. Future violations could lead to fines or suspension of approvals.
- Product Safety: Post-approval use of Viread has reported kidney toxicity, leading to label updates. New safety issues could reduce market acceptance.
- Development Risks: Significant uncertainty remains regarding the commercialization of acquired Triangle assets (e.g., Emtriva, Amdoxovir), including clinical trial success and regulatory approval timelines.
- Foreign Currency: A significant portion of sales is denominated in foreign currencies; a stronger U.S. dollar could negatively impact reported revenues.
Investor Verification Checklist
- Triangle Acquisition Impact: Verify the commercialization timeline and regulatory status of Emtriva (approved July 2003) and other Triangle assets to assess future revenue potential against the $488.6 million IPR&D charge.
- Wholesaler Inventory Levels: Monitor Q3 Viread sales to confirm if the anticipated "pull-back" from Q2 wholesaler stocking occurs, potentially affecting short-term revenue guidance.
- FDA Compliance: Track the resolution of the August 2003 FDA warning regarding Viread promotional practices to assess risk of further regulatory penalties.
- AmBisome Competition: Review European market share data to validate the projected 5-10% sales decline for AmBisome.
- Debt Conversion: Monitor stock price relative to conversion rates of the $595 million in convertible debt to assess potential future dilution.